Project Grant R01HL189083
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $749K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $156,000 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project investigates pulmonary arterial hypertension susceptibility in systemic sclerosis patients carrying the DNASE1L3 R206C genetic variant. Aim 1 will assess the impact of chronic DNASE1L3 deficiency on the pulmonary vasculature in mice...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $421,040 to the University of Texas Health Science Center at Houston on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to support an ancillary research effort investigating mechanisms of response to CD19-redirected plurireceptor natural killer cells in systemic sclerosis and systemic lupus erythematosus. The recipient is conducting an...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Houston System $667,276 in project grant funding on May 20, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds investigation into gene-environment triggers and proteomic pathways that mediate anti-nuclear autoimmunity and systemic rheumatic disease development. The research dissects genetic loci, environmental exposures, gene-by-environment...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Texas Southwestern Medical Center $718,548 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endothelial FLI1 in ischemic heart disease. The funded research examines how Friend Leukemia Integration 1 (FLI1), a transcription factor, governs endothelial cell function and protects against myocardial damage under ischemic stress. Preliminary data using...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $623,286 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate hypoxia-driven NUDT21-mediated alternative polyadenylation in lung and skin fibrosis associated with systemic sclerosis. The project, designated R01AR087804, examines how tissue hypoxia—driven by Raynaud's phenomenon and...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $697,198 to the University of Texas at Austin on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-biased integrin-mediated endothelialization processes for precision vascular graft design. The recipient is conducting research to identify how biological sex affects endothelial cell behavior in response...
- The National Heart, Lung, and Blood Institute awarded Texas Tech University $594,288 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate YAP/TAZ signaling pathways in vascular smooth muscle cell adhesion and migration as a preventive and therapeutic strategy for atherosclerosis. The research comprises three aims. Aim 1 will define how extracellular matrix mechanics regulate vascular smooth muscle cell mechanotransduction. Aim 2 will assess how...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025 through July 31, 2027. The research will investigate the force transduction mechanisms of leukocyte function-associated antigen-1 (LFA-1), a critical CD18 integrin that mediates immune cell adhesion, migration, and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Southwestern Medical Center $613,036 on August 1, 2026, for investigator-initiated research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, "Leveraging Lymphatics to Reverse Heterotopic Ossification," addresses the pathologic formation of extra-skeletal bone occurring in approximately twenty percent of patients following hip...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Arlington $113,788 on August 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how changes in shared public activity spaces—such as walking trails, parks, and sidewalks—affect long-term hypertension risk trajectories in aging adults. The research uses longitudinal data from the nationally representative Health and Retirement Study to identify physical activity-related pathways...